GLPwatch

Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.

Cureus · 2022

Last updated 2026-05-28

A 74-year-old woman with type 2 diabetes started taking liraglutide at a 0.6 mg dose and developed nausea and abdominal swelling within four days. A scan showed her stomach was enlarged without a blockage, suggesting a condition called gastroparesis, and a scope found acid reflux. Her symptoms went away after she stopped the medication, which works by slowing stomach emptying.

AI summary of the abstract below.

JournalCureus, 2022
Citations8
Relative citation ratio0.94
NIH percentile48
Molecules liraglutide
Conditions studied Gastroparesis

Abstract

A 74-year-old woman with type 2 diabetes mellitus presented with nausea and abdomen distension. Four days prior, liraglutide 0.6 mg had been commenced. An abdominal computed tomography scan revealed gastric dilatation without mechanical obstruction which clinically suggested gastroparesis (GP). Her symptoms resolved after liraglutide discontinuation. A gastroscopy revealed reflux esophagitis. Taken together, GP may have developed along with reflux esophagitis due to liraglutide administration. Liraglutide's action inhibits gastric motility. Physicians should be cognizant of the side effects of GLP-1 agonists even in low dose in patients who have gastric emptying symptoms suggesting GP.

Verbatim abstract via PubMed 35983392 ↗

Related research